Article

New prospect for Isogen, Framatome’s JV dedicated to medical isotopes in Canada

July 21, 2020 | 1 min |
Category: medical
ISOGEN Logo
ISOGEN logo
Isogen, Framatome’s joint venture with Kinetrics, Bruce Power and BWXT recently signed a Memorandum of Understanding (MOU) to advance feasibility work for the production of Molybdenum-99 (Mo-99), the isotope most commonly used in nuclear medicine for diagnostic imaging and detection of disease and other medical isotopes in growing demand. These developments are made possible by Framatome’s patented unique technology.

“We are pleased to be working with both BWXT and Bruce Power to extend the use of our technology to the production of Mo-99,” said John D’Angelo, President of Isogen, “It was a logical progression to harness the capacity at the Bruce Power nuclear generating station to fortify Canada’s position to lead in the production of the two most important medical isotopes for therapy and diagnosis, Lu-177 and Mo-99. This new partnership will ensure patients in Canada and throughout the world will have stable and secure access to these critically important medical isotopes.” 

> Read Bruce Power's announcement

 

About Framatome

Framatome is an international leader in nuclear energy recognized for its innovative solutions and value added technologies for the global nuclear fleet. With worldwide expertise and a proven track record for reliability and performance, the company designs, services and installs components, fuel, and instrumentation and control systems for nuclear power plants. Its more than 14,000 employees work every day to help Framatome’s customers supply ever cleaner, safer and more economical low-carbon energy.

Framatome is owned by the EDF Group (75.5%), Mitsubishi Heavy Industries (MHI – 19.5%) and Assystem (5%).